Telesis Bio to delist shares from Nasdaq

Telesis Bio announced that it has notified the Nasdaq Stock Market of its decision to delist the Company’s shares of common stock, par value $0.001 per share and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended. Telesis intends to file a Form 25 with the Securities and Exchange Commission o remove its Common Stock from listing on the Nasdaq Global Select Market on or about September 20. As a result, Telesis expects that the last trading day of its Common Stock on the Nasdaq Global Select Market will be on or about September 30. Telesis will remain subject to continued reporting obligations under Sections 13 and 15(d) of the Exchange Act. As previously noted in the Company’s Current Report on Form 8-K filed with the SEC on April 8 Telesis received a letter on April 3 from the Listing Qualifications Department of Nasdaq notifying Telesis that the Company was not in compliance with the minimum stockholder’s equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders’ equity for continued listing . The Company was granted a 180-day extension to regain compliance with the Stockholders’ Equity Requirement, which expires on September 30 .